Brief: Neurosense's Drug Candidate Shows Early Signals Of Benefit In Alzheimer's Patient-Derived Neurons
10/09/2025 19:42
Sept 10 (Reuters) - Neurosense Therapeutics Ltd NRSN.O: NEUROSENSE'S DRUG CANDIDATE SHOWS EARLY SIGNALS OF BENEFIT IN ALZHEIMER'S PATIENT-DERIVED NEURONS NEUROSENSE THERAPEUTICS- INITIAL PHASE 2 ROAD TRIAL RESULTS DEMONSTRATE IMPROVEMENTS IN BRAIN-CELL CONNECTIVITY HEALTH, WITH FAVORABLE SAFETY PROFILE Source text: ID:nPn7rq37Ya Further company coverage: NRSN.O ((Reuters.Briefs@thomsonreuters.com;))